Quanta bets on medical laser and invests another 5 million euros in Samarate

The El.En group is growing in the medical laser sector and investing in its subsidiary Quanta System, which specialises in this field. Quanta is in fact completing the construction of a new and larger clean room dedicated to the production of sterile optical fibres at its Samarate (Varese) plant, to increase production capacity, on which it has invested approximately 5 million euros. This is an investment in capacity and productivity, which complements the group's investment in research and development. The aim is to maintain Quanta's leadership in the medical sector and with consumables (i.e. fibre optics) sustain its profitability levels, which are the highest in the group in terms of both magnitude and impact on turnover. "The key to all our innovation lies in our investment in research, which has been constant over time and which has involved not only technology but also our people," says Andrea Cangioli, the group's CEO. "We have 1,400 employees, 350 of whom are engaged in research and development activities. What characterises El.En's growth path is precisely this: technological capabilities, attention to people, and the identification of new market needs. All our companies are dedicated to internationalisation: on average, 20 per cent of turnover is generated from Italia, and 80 per cent from exports. For Quanta system the part generated from Italia is only 5%, 95% is exported'.

The Florentine group El.En specialises in laser technologies for the medical, industrial and restoration sectors. Cangioli explains that 'it has grown steadily over time from its foundation more than 40 years ago to today, with an acceleration with the listing in the early 2000s. In 2025 the group had a turnover of 595 million euro, with good profitability: Ebit margin is 13.2%, Ebitda is 92 million euro with Ebitda margin above 15%,' says Cangioli. In the group, the medical sector is the largest with 428 million turnover while the industrial sector has 162 million in 2025. On average about 20% of the turnover is realised in Italia and the rest abroad, between the United States, the Far East, the Middle East and Europe. For Quanta system, the part generated in Italia is only 5%, 95% is exported.

"Despite the expected setback in the Middle East due to the ongoing war, the 2026 guidance forecasts a further 5 per cent revenue growth and improved operating profitability," says Cangioli. The group's growth perspective is based on the fact that 'the technologies it produces meet very specific needs. In aesthetics, we develop machines that enable effective anti-ageing treatments and the reduction of fat masses up to the improvement of skin laxity. The population is ageing and wants to look younger: in the higher age groups there is the greatest disposable income and therefore the greatest willingness to spend on aesthetic treatments. Our body contouring treatments, now that more and more slimming drugs have been introduced, focus on skin tone, also of the face, thanks to the regeneration of collagen that our technologies are able to stimulate,' says Cangioli.

The new investment decision for Quanta system takes place in a social context in which demand for laser treatments is steadily increasing in the medical sector. Within the medical and aesthetic systems sector, which accounts for more than 74% of the El.En group's turnover, medical service accounts for 20%. In 2025, the turnover of the medical service sector was EUR 429 million, an increase of 4.4%, of which half was related to fibre optics. About 50% of sales for medical service are sterile optical fibres for surgical applications. Orders and sales, particularly in Italia, the Far East and Germany, but also in the United States, are once again rewarding the group's ability to equip its sales force with innovative solutions in terms of both technology and application and function. Today Quanta system, one of the group's companies exclusively dedicated to the medical sector, opens its doors to Italian and foreign investors to show the great innovation of its solutions and the expansion of its clean room for the production of sterile optical fibres. "The story of Quanta system, which is the group's leading company in terms of profitability, is a story that from the outset shows a strong vocation for innovation," Cangioli recounts. "In fact, it was founded in the 1980s as a spin-off of CISE for advanced laser technologies and has always had very high innovative standards. Then, after leaving the scientific sector, the company focused on medical applications in the early years of the century. Lasers for urological surgery applications are always used with a single-use or multi-use optical fibre, so as the installed base of machines has grown, so has the use of optical fibre. We expect a volume growth of up to 10% per year in the medium term'. Hence the decision to increase the production of sterile optical fibres for surgical applications.